<DOC>
	<DOCNO>NCT02927483</DOCNO>
	<brief_summary>The trial design randomize , multicenter , open label , comparative , 6 month , clinical study .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Endolex Forte VErsus Diosmin Hesperidin Reducing VeNous Insufficiency</brief_title>
	<detailed_description>A randomize , multicentered , open label , comparative study ass efficacy safety Endolex Forte® versus combination micronized diosmin ( 450 mg ) micronized hesperidin ( 50 mg ) reduce symptomatology patient diagnose Chronic Venous Insufficiency rat functional class CEAP 1-4 , period 6 month .</detailed_description>
	<mesh_term>Venous Insufficiency</mesh_term>
	<criteria>Patients , male female age 18 75 year old BMI≤40 Presence chronic venous insufficiency rat functional class CEAP 14 Patients diagnosed superficial vein thrombophlebitis skin reaction redness , swell , fever pain symptoms.or patient present painful venous symptomatology lower limb least 30 day . Willing able give write informed consent prior participation trial Patients expect compliant study treatment Known allergy product 's ingredient Pregnancy breastfeed Patient involve clinical trial Deep vein thrombosis Stasis dermatitis The patient take nonsteroid antiinflammatory drug include oral , topical cream patch form ) Open ulcer low extremity amputation Patient treat venotonic treatment vascular protectants assimilate dietary supplement homeopathic treatment diuretic within 15 day prior inclusion Patient present permanent oedema , Patient history lower limbs trauma responsible sequel pain NYHA III IV Heart Failure Renal Failure Untreated uncontrolled Arterial Hypertension Hepatic Failure History know liver disease hepatitis A , hepatitis B , C. Malignant neoplasm , etiology , receive type anticancer treatment , unless properly treat evidence recurrence last five year Previous history alcoholism , drug abuse , psychological emotional problem last 5 year invalidate Informed Consent Form restrain participant 's ability comply requirement protocol . Immobility .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Venous Insufficiency</keyword>
</DOC>